GLP-1 & Gallbladder Disease: What Ozempic & Mounjaro Do to Your Gallbladder (Weightloss Dr Explains)

[00:00:00]GLP-1 medications are some of the most effective drugs that we have right now.

[00:00:04]They lower blood sugar and they help people lose weight that diet alone previously couldn't do. But, they also carry a side effect that doesn't get talked about nearly enough. They raise your risk of bladder and bile duct disease. And honestly, I've been seeing more and more of this over the past few months while working in the hospital, which is what prompted me to make this video in the first place. The good news though is that this risk is well understood. We know why it happens and what actually lowers the odds. That's what this video is going to be about.

[00:00:29]for most people, the benefits of a GLP-1 medication like Ozempic, Wegovy, or Mounjaro, and even the newer drugs like tirzepatide overwhelmingly outweigh the risk. The problem isn't that gallbladder issues can't happen. The problem is that most people have no idea why they happen, who is actually at risk, or what they can do to dramatically reduce their chances of ending up in the emergency room. So, in this video, I'm going to break down the actual science behind GLP-1 medications and gallbladder disease. I'm going to explain whether it's the medication or the weight loss that's causing the problem, and I'm going to reveal which drugs appear to carry the highest risk. But most importantly, I'm going to show you exactly what symptoms should never be ignored because understanding this risk could be the difference between catching a problem early or finding yourself in the operating room wondering what went wrong. I'm Dr. Kevin Joseph, a board-certified internal medicine physician. I prescribe these medications daily and I even take a GLP-1 myself as a part of how I lost over 150 lb. So, I'm not here to scare you off a class of drugs that I genuinely believe is one of the most important things to happen to metabolic medicine. But, I'm also a doctor who sits across the table from a patient when their gallbladder goes bad and they need surgery. So, here's the plan. First, we're going to talk about the biology. Four specific reasons this happens, two from the drug and two from the weight loss itself. Then every condition it can lead to from minor to serious. And finally, exactly how to lower your risk. So, let's get started.

[00:01:46]Let's start with a quick anatomy lesson.

[00:01:48]Your gallbladder is a small pouch. Think of it as a holding tank or a reservoir.

[00:01:52]Your liver constantly makes bile, which is a detergent that your gut uses to break down fat. Between meals, that bile gets routed into the gallbladder, where it sits and concentrates. Then, when you eat something fatty, your gut releases a hormone called cholecystokinin, or CCK, and that hormone tells the gallbladder to squeeze. Bile shoots down the bile duct into your intestine, and fat gets emulsified, or broken down. Now, here's the issue. A gallbladder gets into trouble for two reasons. Either the bile inside it becomes too thick and crystal prone, or the gallbladder stops squeezing properly, and the bile just sits there and stagnates. Thick bile plus stagnant bile equals stones. Stones plus inflammation equals a medical emergency. And this isn't just a small medical issue. We're talking about an organ that, when it goes bad, can mean ER visits, emergency surgery, infection, and, in the worst-case scenario, a pancreatitis attack. Now, let's look at the numbers. In 2022, JAMA Internal Medicine, which is a widely popular medical journal, published a meta-analysis. They pulled 76 randomized control trials, over 103,000 patients.

[00:02:52]And what they found was a relative risk of 1. 37 for gallbladder or biliary disease in people on GLP-1 receptor agonists. That's a 37% relative increase. Now, that's relative risk. It tells you how much one group's odds change compared to another, but it says nothing about how common the problem actually is. Absolute risk is the number that we care about, because that's the number that actually affects you, your real chance of something happening. You know, you hear it like three out of 100 people. So, yes, a 37% increase sounds terrifying, but we are smarter than that. And I'm going to give you the number that actually matters, the absolute risk. When they did the math, the excess came out to roughly 27 additional events per 10,000 patients treated per year, or 0.27%. Now, let's break down the meta-analysis even further. When they separated the data by dose, the entire risk lived in the high-dose group, with a relative risk of 1.56. The low-dose group relative risk was 0.99. This basically means that, at low doses, statistically no measurable increase in gallbladder disease existed.

[00:03:50]When they separated the data by duration, treatment longer than 26 weeks carried the risk. Short courses did not.

[00:03:57]And the biggest factor of all, when they separated by why people were taking the drug, diabetes use came in at a relative risk of 1.27, but weight loss came in at a relative risk of 2.29, more than double. Here's how I want you to read the pattern. The higher the dose, the longer you're on it, and the more weight that you're losing, the higher the gallbladder risk becomes. The harder and faster you push the weight off, the harder you lean on the gallbladder. And just so you know, it's not one vague lump called gallbladder disease. The same medical paper broke it down into specific diagnoses. Gallstones had a relative risk of 1.27. Cholecystitis, which is an inflamed gallbladder, had a risk of 1.36. Biliary disease, meaning that the ducts were infected, had a risk of 1.55. And actually needing your gallbladder surgically removed had a risk of 1.70. Every single category was elevated. The one thing that was not significantly increased was biliary tract cancer. And I want to be transparent about that. The fear that these drugs cause gallbladder cancer is not supported by the data. Now, the question is, are some of these drugs worse than others? And the answer is yes. And this matters because the term GLP-1 is not just one drug. Liraglutide, one of the OG GLP-1s, which is a daily injectable, brand name Saxenda or Victoza, has the strongest signal of the whole class. In the meta-analysis, its relative risk was 1.79. In the SCALE trial, liraglutide at 3 mg weight loss dose produced acute gallstone disease in 3.1% of patients versus 1.9% on placebo.

[00:05:22]And the people who had gallbladder events had lost more weight than the people who didn't. The weight loss itself was the driving factor.

[00:05:28]Semaglutide, aka Ozempic, Wegovy, and Rybelsus, is pretty interesting.

[00:05:33]Overall, it didn't reach statistical significance in the pooled analysis with a relative risk of 1.28. But if you push it to the highest dose, its relative risk jumps to 1.58. The Wegovy label spells it out. Cholelithiasis, also known as gallstones, showed up in 1.6% versus 0.7% on placebo for the injection and 2.5% versus 1% for the oral tablet.

[00:05:53]Tirzepatide, aka Mounjaro and Zepbound, the dual GIP and GLP-1 agonist, actually has its own dedicated meta-analysis from 2025, which showed a relative risk of 1.52 for biliary disease and 1.67 for gallstones specifically. In the SURMOUNT weight loss trials, cholelithiasis occurred in around 2.5%, cholecystitis 0.7% versus 0.2% on placebo. Tirzepatide drives bigger weight loss than semaglutide, and the gallbladder numbers track right along with that, exactly what you'd expect. Okay, so now let's talk about why does this happen? There are four mechanisms, and they split neatly into two from the drug and two from the weight loss. Mechanism one, the drug shuts down the squeeze. Remember CCK, which is the hormone that tells your gallbladder to contract or squeeze?

[00:06:36]Well, GLP-1 suppresses CCK. Less CCK means a lazier, slower squeeze. There's a beautiful randomized study where they put people on liraglutide, and they actually measured gallbladder empty. The interesting thing is that the gallbladder still emptied about the same total amount, but the time it took to reach maximum concentration went from about 77 minutes on placebo to about 151 minutes on the drug, almost double. The problem is that bile that sits is bile that thickens and starts forming crystals. The gallbladder isn't paralyzed, it's just sluggish and late, and sluggish and late is exactly the environment that stones love. Mechanism two, the drug changes the structure of the bile itself. This is a little bit more complex, but the gist of it is that your body controls bile through a set of sensors. Think of these as a thermostat for bile acid production and gallbladder muscle tone. GLP-1 activation nudges that whole system towards two bad outcomes, bile that's more loaded with cholesterol and a gallbladder muscle that's much more relaxed. Both of these significantly increase the risk of stone formation. So, those are the two mechanisms that the medication affects directly. Now, let's talk about the two mechanisms from weight loss, and these have been known in medicine for a decades, long before GLP-1s even existed. Mechanism three, rapid weight loss floods the bile with cholesterol.

[00:07:48]When you lose fat quickly, all that stored cholesterol has to leave your body somehow, and a big chunk of it exits through bile. Your liver dumps cholesterol into bile faster than bile can keep it dissolved. We call that supersaturation, and about 80% of gallstones are cholesterol stones. This is the analogy that I like to use. It's like stirring sugar into iced tea. A little dissolves clear, but keep dumping sugar in it, and eventually it stops dissolving and starts settling as crystals at the bottom. Rapid weight loss is dumping cholesterol into bile faster than it can dissolve. Crystals settle, and crystals become stones.

[00:08:21]Mechanism four, you're eating less, so the gallbladder barely gets the signal to squeeze at all. On a GLP-1, you're eating smaller meals, or sometimes skipping meals entirely because you're just not hungry. But the gallbladder only squeezes when food, especially fat, shows up. Fewer, smaller, leaner meals means fewer squeezes, which means more stagnation. The most dramatic proof of this isn't even from weight loss. It's from IV nutrition. When patients are fed entirely through a vein, and their gut gets nothing, gallbladder sludge shows up in about half of them within four to six weeks. And in long-term cases, it approaches a 100%. A gallbladder that never gets told to squeeze will sludge up almost every single time. So let's take a step back and look at all four.

[00:09:00]The drug slows down the squeeze. The drug worsens the bile recipe. The weight loss supersaturates the bile with cholesterol, and the eating pattern removes the trigger to empty. So clearly, this isn't some mysterious side effect. So when someone asks me, you know, is it the drug or the weight loss?

[00:09:15]Honestly, my answer to them is that it's both, and they multiply each other. Now let's walk the actual spectrum of what can go wrong, from least to most dangerous, because the term gallbladder disease hides a lot of different problems. Gallbladder sludge is the first one. It's bile that's starting to thicken. Most people never even know that they have it. It's the earliest sign of stagnation. Next up is called cholelithiasis, aka gallstones. The relative risk is 1.27 in the meta-analysis that we talked about earlier. The catch is that most stones are silent. You can be walking around even right now with a gallbladder full of stones and feel completely fine. The trouble starts when the stones start to move. Next up is biliary colic. This is what you feel when a stone temporarily plugs the gallbladder's exit. Here's a classic story that I want you to picture. Intense pain in the right upper belly, often after a meal, sometimes radiating to the right shoulder or back, lasting minutes to a few hours, and then fading away when the stone slips back.

[00:10:05]Cholecystitis is the next level up. It's a relative risk of 1.36, and this is the one that puts people in the hospital.

[00:10:12]Now the stone is stuck. The gallbladder is inflamed and often times infected.

[00:10:15]This is frequently a surgical situation.

[00:10:18]Next up is choledocholithiasis. This is when a stone escapes the gallbladder and lodges in the common bile duct. This is the one that can cause jaundice, which is yellowing of the eyes and skin, because bile can't drain. It can cause inflammation of your liver. This is a medical emergency because the stone needs to be taken out as soon as possible. And often times they'll take out your gallbladder as well. And then the connection that most people never make, pancreatitis. Your bile duct and your pancreatic duct share the same exit into the intestine. A stone parked at that junction can back up into the pancreas and trigger gallstone pancreatitis. In the scale trial, five of six gallstone related pancreatitis cases were in the drug group. So gallbladder story and the pancreatitis story may be far more connected than we actually think. Now the part you actually came for. What do we do with all of this information? First, know your risk profile. Female sex is a genuinely independent risk factor. Add rapid weight loss and known or prior gallstones, and you're really increasing your risk. Remember, if your baseline risk is higher, then you should be paying closer attention. Not avoiding the drug, just paying close attention.

[00:11:17]Second, and this is the most actionable thing under your control, don't crash diet. The risk increased along with the speed and magnitude of weight loss in every data set that we looked at. So titrate up slowly and let your body lose weight at a sustainable pace. The slow approach isn't just easier on your nausea and your muscle mass. It's easier on your gallbladder as well. This is one more reason I'm such a huge believer in a low and slow approach rather than racing to the highest dose as fast as possible. Third, know the warning signs because catching this early honestly changes everything. Persistent pain in the right upper quadrant of your abdomen, especially after fatty meals, nausea and vomiting that's different from your usual GLP-1 discomfort, fever, that's even more concerning cuz that points towards infection such as cholecystitis or cholangitis. And jaundice, which is the most dangerous of all, is yellowing of your skin or eyes.

[00:12:04]That means a duct may be blocked and that is a same-day do not wait evaluation and go right to the ER. If those show up, the workup is straightforward. An ultrasound of the right upper quadrant is the first test, then a HIDA scan, and blood work if we're worried about the ducts being blocked or the pancreas. So, let's put this all together. GLP-1 medications do increase gallbladder and biliary disease. It's in the FDA labels and it spans the whole spectrum. Sludge, stones, biliary colic, cholecystitis, duct stones, and pancreatitis. The risk increases with the higher doses, longer duration, and faster weight loss. But here's the reframe, and it's the whole point of me making this video. The absolute risk is small, on the order of a couple dozen extra events per 10,000 patient years. And at the same time, these drugs are reducing heart attacks, strokes, and death. The mistake I see constantly is treating this as black and white. Either GLP-1s are miracle drugs with no downside, or they're dangerous and you should not be on them. The truth though is that these drugs are a powerful, beneficial class of medications with mostly predictable side effects. And because it's predictable, you have actual control over a lot of it. Go slower, know the symptoms, and don't crash diet on top of the drug. The gallbladder isn't a reason to avoid these medications, it's a reason to use them like an adult who understands what's happening inside their own body, and now you do. I'll see you next time.